ACOR stock news

Acorda (ACOR) beat earnings and revenue estimates in the fourth quarter of 2019. Read more
Acorda (ACOR) reports lower-than-expected loss in the fourth quarter while revenues beat estimates. Read more
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the fourth quarter and full year ended December 31, 2019. “INBRIJA’s launch was an important milestone for Acorda in 2019. It is the first and only approved inhalation therapy for the treatment of OFF periods in Parkinson’s disease. In 2020, our focus will be on increasing awareness of and driving demand for INBRIJA among people with Parkinson’s,” said Read more
During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija. Read more
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2019 update and financial results on Thursday, February 13 at 8:30 a.m. ET. To participate in the conference call, please dial (833) 236-2756 (domestic) or (647) 689-4181 (international) and reference the access code 4665685. The presentation will be available on the Investors section of www.acorda.com. A replay of the call will be avai Read more
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided 2019 highlights and 2020 guidance and priorities at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. “The approval and launch of INBRIJA was an important milestone for Acorda; we believe this product will become a standard of care in the treatment of OFF episodes in Parkinson’s Disease,” said Ron Cohen, M.D., Acorda’s President and CEO. “In 2020, we plan to build on our experience from the Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the appointment of healthcare industry veteran Kimberly Whelan as VP, Market Access, as it prepares for a potential Twirla commercial launch) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Therapeutics Inc (NASDAQ: APLT ) Ascendis Pharma A/S (NASDAQ: ASND ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) Epizyme Inc (NASDAQ: EPZM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) INNATE PHARMA S/S ADR (NASDAQ: IPHA )( announced EMA acceptance of regulatory application for drug to treat hairy cell leukemia) The Medicines Company (NASDAQ: MDCO ) Mesoblast limited (NASDAQ: MESO )(announced submission of safety and efficacy data as part of rolling BLA submission for remestemcell-L for the treatment of children with steroid-refractory acute graft versus host disease) Mirati Therapeutics Inc (NASDAQ: MRTX ) Nevro Corp (NYSE: NVRO ) NuVasive, Inc. (NASDAQ: NUVA ) Otonomy Inc (NASDAQ: OTIC ) Syneos Health Inc (NASDAQ: SYNH ) Urovant Sciences Ltd (NASDAQ: UROV ) Veru Inc (NASDAQ: VERU ) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 2) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Evelo Biosciences Inc (NASDAQ: EVLO ) Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Wave Life Sciences Ltd (NASDAQ: WVE ) Xeris Pharmaceuticals Inc (NASDAQ: XERS ) Stocks In Focus Acorda Gains After Hedge Fund Hikes Stake Acorda Therapeutics … Read more
Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or the “Company”) today announced it has successfully completed its previously announced private ex Read more
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that its Board of Directors has elected John Kelley to serve as non-executive board Chair, effective November 25, 2019. Mr. Kelley has been a board member at Acorda since 2008. “I am delighted that John will be chairing Acorda’s board,” said Ron Cohen, M.D., Acorda's President and CEO. “John has extensive senior leadership and commercial experience in the biopharmaceutical industry, and we expect that he wi Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov. Read more
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Jane Wasman, President, International & General Counsel, is resigning from the company effective at the end of this year. Ms. Wasman plans to expand her role as a member of corporate boards, and to provide consulting services within the life sciences industry. She also will serve as a consultant to Acorda following her departure. “Jane has contributed meaningfully to Acorda’s successes over the pas Read more
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) provided a financial update for the quarter ended September 30, 2019. “Our focus has been on ensuring physician awareness and clearing a pathway for access to Inbrija. We have been receiving encouraging feedback on Inbrija from physicians suggesting it should become standard of care for the treatment of Parkinson’s. This is consistent with market research from healthcare professionals and people living with Parkinson’s ind Read more
Acorda (ACOR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise quarter) Edwards Lifesciences Corp (NYSE: EW )( reported better-than-expected third-quarter results) Frequency Therapeutics Inc (NASDAQ: FREQ ) (IPOed Oct. 3) GlaxoSmithKline plc (NYSE: GSK )(FDA approved expanded use of Zejula) Novo Nordisk A/S (NYSE: NVO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 24) Acorda Therapeutics Inc NASDAQ: ACOR) (announced restructuring plan, including the elimination of 25% of its workforce) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) bluebird bio Inc (NASDAQ: BLUE ) (announced resignation of chief strategy officer) Brickell Biotech Inc (NASDAQ: BBI ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Gritstone Oncology Inc (NASDAQ: GRTS ) KemPharm Inc (NASDAQ: KMPH ) MacroGenics Inc (NASDAQ: MGNX ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) OpGen Inc (NASDAQ: OPGN ) )(announcing pricing of previously-announced underwritten common stock offering) Opko Health Inc. (NASDAQ: OPK )(announced a follow-on offering) Orgenesis Inc (NASDAQ: ORGS ) Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN ) Titan Medical Inc. (NASDAQ: TMDI ) Stocks In Focus Melinta Gets FDA Nod For Baxdela Label Expansion; Launch to Be Delayed Due to Liquidity Concerns Melinta Therapeutics Inc (NASDAQ: MLNT ) announced FDA approval for Baxdela for the treatment of adult patients with community-acquired bacterial pneumonia, or CABP, caused by designated succeptible bacteria. Read more

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

Proudly Made At

ROCKIT